The National Institute on Deafness and Other Communication Disorders awarded Vulintus $1.5M for a two-year Phase II SBIR project to run a multi-site efficacy study of the OptiSpeech system for speech therapy and to create commercial-ready beta systems. Holle Carey is the principal investigator.
Vulintus Starts On-Field Testing of NeuroTriage System
Working with the University of Texas at Dallas, Vulintus is testing our NeuroTriage system for on-field diagnosis of concussions on the sidelines of high school football games. Here's our CEO Robert Rennaker in an Associated Press news story:
Vulintus' NeuroTriage System in the News
Vulintus CEO Robert Rennaker has been making the rounds in the local news to talk about concussions in high school sports and how the NeuroTriage system can help.